U.S. group raises pricing recommendation for Gilead's remdesivir in COVID-19

The Institute for Clinical and Economic Review (ICER) said its recommendation change stemmed from recent clinical data, updated cost estimates, public comments and interactions with Gilead.What Gilead could charge for remdesivir in the United States after its pledged donations are used up has been a topic of intense debate, with experts suggesting that Gilead would need to avoid the appearance of taking advantage of a health crisis for profits.